|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
15 August 2022 |
|
Main ID: |
NCT00326625 |
|
Date of registration:
|
16/05/2006 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
|
|
Scientific title:
|
A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS) |
|
Date of first enrolment:
|
July 27, 2006 |
|
Target sample size:
|
366 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT00326625 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
Belgium
|
France
|
Germany
|
Israel
|
Italy
|
United Kingdom
| | |
|
Contacts
|
|
Name:
|
Merav Bassan, PhD. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Teva Pharmaceuticals Industries LTD |
| | |
|
Key inclusion & exclusion criteria
|
|
Health Condition(s) or Problem(s) studied
|
|
Source(s) of Monetary Support
|
|